# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-20-060162
Filing Date
2020-05-12
Accepted
2020-05-12 16:03:51
Documents
6
Effectiveness Date
2020-05-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | tm2019153d2_defa14a.htm | DEFA14A | 23089
2 | GRAPHIC | tm2019153d2_defa14a-img01.jpg | GRAPHIC | 214484
3 | GRAPHIC | tm2019153d2_defa14a-img02.jpg | GRAPHIC | 297178
4 | GRAPHIC | tm2019153d2_defa14a-img03.jpg | GRAPHIC | 88380
5 | GRAPHIC | tm2019153d2_defa14a-img04.jpg | GRAPHIC | 43079
6 | GRAPHIC | tm2019153d2_defa14a-img05.jpg | GRAPHIC | 14396
| Complete submission text file | 0001104659-20-060162.txt |  | 930586

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-50626 | Film No.: 20869047
SIC: 2834 Pharmaceutical Preparations